Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis

Waldenström macroglobulinemia (WM) is a rare, incurable low grade lymphoma following a relapsing trajectory. Management strategies have evolved with the introduction of targeted therapy including new classes of Bruton tyrosine kinase inhibitor (BTKi). Treatment may however be limited particularly at...

Descripción completa

Detalles Bibliográficos
Autores principales: Khwaja, Jahanzaib, Uppal, Encarl, Baker, Robert, Trivedi, Kajal, Rismani, Ali, Gupta, Rajeev, Proctor, Ian, Kyriakou, Charalampia, D'Sa, Shirley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713031/
https://www.ncbi.nlm.nih.gov/pubmed/36467794
http://dx.doi.org/10.1002/jha2.597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713031/
https://www.ncbi.nlm.nih.gov/pubmed/36467794
http://dx.doi.org/10.1002/jha2.597

Ejemplares similares